Transaction details and context
According to a Form 4 filed with the Securities and Exchange Commission, Rui Avelar, an officer at Evolus, Inc. (NASDAQ: EOLS), executed sales of 3,119 shares of the companys common stock on March 20, 2026. The disposals were recorded at a weighted average price of $4.75 per share for an aggregate value of $14,815. The trades were completed in multiple executions with individual prices ranging from $4.7498 to $4.7701.
After these sales, Avelar directly holds 427,423 shares of Evolus. The filing notes that the sales were carried out pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person and that the shares sold were required to be sold to cover tax withholding obligations in connection with the settlement of restricted stock unit awards.
Market position and recent company developments
The stock has been trading close to its 52-week low of $4.09 and has declined approximately 65% over the past year. Separately, Evolus reported fourth-quarter 2025 revenue of $90.3 million, a slight shortfall versus the $90.75 million forecast. That revenue miss has been highlighted as a notable result for the company.
Corporate governance changes were also disclosed: the company adjusted its board composition following the departure of Simone Blank. As part of that process, Vikram Malik was reclassified from a Class III director to a Class II director to address an imbalance in the firms classified board structure. Investors and analysts are monitoring these developments.
Valuation note
According to InvestingPro analysis cited in the filing, Evolus appears undervalued at current market levels. The platform tracks more than eight additional key metrics for the company, which is described as a $304 million enterprise in that analysis.
Key takeaways
- The sale of 3,119 shares by Rui Avelar was executed under a Rule 10b5-1 plan and was intended to satisfy tax-withholding obligations tied to RSU settlements.
- Evoluss stock is trading near its 52-week low after a roughly 65% decline over the last year, while the company posted a slight Q4 2025 revenue miss versus analyst expectations.
- The company has adjusted its board classifications following a director departure, with Vikram Malik reclassified to restore balance in the classified board structure.
Relevant sectors
These developments touch the healthcare and biotech sectors, as well as the small-cap equities market where corporate governance, insider transactions, and near-term revenue performance can influence investor sentiment and stock liquidity.
Limitations
The filing and related disclosures provide specific transactional and corporate governance facts but do not offer forward-looking guidance or management commentary on future operations. Where analysis from InvestingPro is cited, the article reports that assessment without endorsing or expanding on its methodology.